Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 28, 2024) - Investorideas.com, a go-to investing platform covering health and wellness and biotech stocks issues a snapshot looking at news and developments for the global GLP-1 receptor agonist market, featuring new player in the market, Integrated Ventures, Inc. (OTCQB: INTV). Read the full article at Investorideas.com https://www.investorideas.com/News/2024/biotech/08280GLP-1.asp According to Research and Markets, The global GLP-1 ...

TAMPA, Fla. , Aug. 28, 2024 /PRNewswire/ -- Integrated Ventures, Inc. (OTCQB: INTV), a diversified portfolio holdings company, is excited to announce its strategic entry into the rapidly expanding health and wellness sector. The initial phase of this transition will be led by the newly established subsidiary, MedWell USA, LLC, which will serve as a B2B Procurement Agent for a variety of pharmaceutical products, with a particular focus on the booming medical weight loss and GLP-1 markets. MedWell USA will be ...

SUNNYVALE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Ozempic®, Wegovy® and compounded semaglutide through a weight loss program on its telehealth platform, providing consumers with access to affordable weight management care through a convenient subscription-based model. If prescribed, Lemonaid Health patients will now have access to once-weekly injectable GLP-1 medication offerings ...

Ozempic remains on top in the GLP-1 drug market -- but for how long? The anti-obesity drug market could one day be worth $100 billion. It's a massive opportunity in healthcare, and two companies that are leaders in that space today are Eli Lilly (LLY 0.23%) and Novo Nordisk (NVO 1.42%). Unsurprisingly, these are also two of the most valuable healthcare companies in the world right now. They have been rivals for decades, and the growing popularity of their respective glucagon-like peptide 1 (GLP1) drugs ensu ...

SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, has started screening patients for a Phase 2 clinical trial (CBeyondTM) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody. The study will assess the ability of nimacimab as a nextgeneration weight loss therapeutic to safely and effectively reduce weight in patients w ...

文章核心观点 - 公司正在加速增加使用个性化解决方案的订阅用户,这是一个非常积极的迹象 [4][5] - 公司通过在现有和新的专业领域创新和扩展个性化解决方案,正在获得市场份额 [1][4][5] - 公司正在投资人工智能和基础设施,以扩大其定制解决方案的规模并提高治疗效果,这应该会带来运营杠杆 [6] - 公司的体重管理业务正在快速增长,预计到2025年将超过1亿美元收入 [6] - 公司的盈利能力正在不断提高,调整后EBITDA利润率已达12.5% [6] 根据目录分别总结 积极因素 - 订阅用户数量加速增长,特别是使用个性化解决方案的用户 [4][5] - 公司正在不断创新和扩展个性化解决方案,以吸引新用户并转化现有用户 [1][4][5] - 公司的体重管理业务增长迅速,收入占比已达5% [6] - 公司的盈利能力持续提升,调整后EBITDA利润率大幅提高 [6] 潜在风险 - 复合GLP-1注射剂可能只是一种时尚,存在副作用和监管风险 [7][8] - 随着礼来和诺和诺德等公司增加GLP-1药物产能,公司的复合GLP-1需求可能会正常化 [8] 总结 总的来说,公司正在加速增加使用个性化解决方案的订阅用户,并通过不断创新和扩展产品组合来获得市场份额。同时,公司的体重管理业务增长迅速,盈利能力也在持续提升。尽管复合GLP-1注射剂存在一些潜在风险,但这并不是公司增长的唯一驱动因素。综合来看,公司仍有很大的上涨空间。[9][10]

SAN DIEGO, Aug. 20, 2024 /PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB: EVFM) is raising awareness of the potential impact these medications may have on the effectiveness of oral contraceptives. With an increasing number of women turning to GLP-1 medications for weight management and glycemic control, the need for reliable non-oral contraceptive options has never been more acute. GLP-1 receptor ...

● . ● | --- | --- | |---------------------------------------------------|-------| | | | | Defence Investigates the Application of the Accum | | | Hydrogel Technology to Deliver GLP-1 in Order to | | | Increase the Treatment Efficacy of Diabetes and | | August 19, 2024 9:27 AM EDT | Source: Defence Therapeutics Inc. Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company ...

文章核心观点 - 新兴的小型医疗公司正在开发GLP-1减肥药,对诺和诺德和礼来构成潜在威胁 [3] - 但更大的担忧是来自于拥有大量资源和制造能力的大型医疗公司,其中罗氏可能成为诺和诺德和礼来的主要竞争对手 [4][5] 罗氏的多管齐下策略 - 罗氏正在开发多种GLP-1减肥药,其中CT-388和CT-996都显示出良好的疗效 [6][7][9] - CT-388是每周注射剂,在24周内帮助患者减掉近19%的体重,与礼来的Zepbound相当 [7] - CT-996是每日口服药,在4周内帮助患者平均减掉6.1%的体重,有望吸引更广泛的患者群体 [9] 罗氏有望提前进入市场 - 罗氏原本预计要到下个十年才推出减肥药,但现在正在加快这些药物的开发,可能在2028年前推出 [10][11] - 这表明罗氏正在认真对待这个市场,越早进入市场,Zepbound和Wegovy就越难被新药取代 [11] 罗氏的潜力不容忽视 - 罗氏是一家市值超过2500亿美元的大型医疗公司,将成为诺和诺德和礼来需要担心的强劲竞争对手 [12] - 尽管罗氏进入GLP-1减肥药市场还需要几年时间,但投资者不应低估其潜力 [12]

Mounjaro and Zepbound are likely to be Eli Lilly's top two products in the very near future. For a top drugmaker like Eli Lilly (LLY -1.01%), developing new drugs is key to ensuring that its business continues to grow. Patents don't last forever, so continuing to innovate is the only surefire way to be successful and remain a top company in the healthcare industry. In the past couple of years, the company has obtained approvals for multiple new products, including Mounjaro for diabetes, Zepbound for weight ...